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Results. A signiﬁcant decrease in the value of the VAS due to swallowing was detected, after sublingual fentanyl administration.
After 4.5–5.5 weeks the difference reached on average 6 points in the VAS (p=0.001). In the clinical history of 49.18% of patients,
the beginning of pain relief was equal to/lower than 5min. After 10min in 73.77% of patients. Patient’s weight throughout the
study proved to be signiﬁcantly lower at all time points compared with baseline. Most prevalent adverse events were nausea
(42%) and constipation (39%).
Conclusions. Sublingual fentanyl probed to be efﬁcacious and fast acting, since there is a signiﬁcant decrease in the VAS at all
time points compared to baseline, and an important percentage of patients noticed pain relief in 5min or less.
http://dx.doi.org/10.1016/j.rpor.2013.03.582
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Introduction. The progressive incorporation of concomitant RT-CT in clinical practice, leads to increase side effects during and
after treatments. Pain is present in different clinical conditions: oral mucositis, esophagitis, urethritis, proctitis, radiodermatitis.
Objectives. The main objective of the study was to evaluate the intensity of breakthrough pain induced by cancer treatments
including radiation therapy, alone or associated with chemotherapy. As a secondary objective was to assess the efﬁcacy of
breakthrough pain treatments used.
Materials and methods. Retrospective observational study in 110 patients. Inclusion criteria were: outpatients over 18 years, with a
diagnosis of cancer at any site, regardless of stage, treated with RT or RT/QT. Patients were suffering severe breakthrough induced
by treatments with or without medication prescribed, and intensity using VAS was >6 in the last 24–48h.
Results. 67.3% of patients were male and 32.7% female. Mean age was 63 years. Breakthrough pain was produced by ‘mucositis’
(55.2%), followed by ‘esophagitis’ and ‘other’ (17.7% and 16.7% respectively). In the VAS, there was a decrease in the values as
the study progressed (control0 = 6 vs. Control3 = 3). We found signiﬁcant differences in all controls compared to baseline values
(p-value<0.0001).
Conclusions. Breakthrough pain induced by RT or RT/QT is a prevalent problem in the radiotherapy departments, mucosal inﬂam-
mation is the main cause of this pain. Transdermal fentanyl is the most frequent medication for baseline pain control. Results
show the efﬁcacy of the treatment of breakthrough pain induced by RT or RT/QT with sublingual fentanyl, since there is a signif-
icant decrease in VAS compared to baseline. Treatment satisfaction was rated good or excellent by 85.3% of patients and 92.7%
of physicians.
http://dx.doi.org/10.1016/j.rpor.2013.03.583
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Introduction. The acute esophagitis (AE) is one of the most important adverse effects of the radio chemotherapy (RQT) in lung
cancer, most of all if it’s perform concurring and the RT fractionated. Data published don’t allow to formulate exact recommen-
dations not dosimetrics nor therapeutics and it doesn’t exist a demonstrated effective prevention. The intranasal fentanyl with
pectin (INFP) is indicated in the oncological irruptive pain. It holds a great quickness of action and bioavailability and also avoids
the oral way.
Objectives. Evaluate the effectiveness of the INFP administrated in a precocious way in the regulation of the esophagitis in patients
with concurrent RQT for CPNCP III A–III B and CPCP-EL.
Method. Of all patients included in the study, it was calculated the probability of esophagitis G3-4 using a nomogram published
by Dehing–Oberige in 2010. In patients with a higher risk level analgesia was initiated in an early manner (EVA=0>3), combin-
ing transdermic fentanyl and INFP, to avoid the adverse effects due to swift escalade of opiods. The entitlement of INFP was
accomplished systematically in the nursing consulting room.
Results. After having treated the ﬁrst twelve patients, with a 2 months minimum follow-up process, the preliminaries results
are: the 75% were CPNCP III A–III B and the 25% CPCP-EL. Dose of RT 66Gy and 45Gy (2 f/day) respectively and the chemotherapy
CDDP-docetaxel andCDDP-VP16. The average dose of RTwhenesophagitiswas detected: 40′8Gy. Thepeak esophagitis (CTCAEv4),
G2:8p, G3:4p. Measured pain by EVA scale: average 6.1. Average dose of transdermic fentanyl 30g/h/72h. Average dose of INFP:
4g/h. There were not produced an interruption of the treatment in two patients, it was not possible to keep the oral ingestion.
The adverse effects were poor and slight (they will be speciﬁed in the congress).
Conclusions. These preliminaries data suggest that the intranasal fentanyl with pectin is efﬁcacious for the regulation of the pain
in the AE by RQT. The early start and the systemic entitlement in the nursing consulting room make for the accomplishment
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of the medication and reduce the adverse effects. The strict control of the pain can modify the staging, understating, of the
esophagitis.
http://dx.doi.org/10.1016/j.rpor.2013.03.584
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Purpose. To evaluate and control breakthrough pain (BP) episodes in advanced cancer patients undergoing radiotherapy during
proceedings and maneuvers necessary to receive treatment, and assess the ability of Fentanyl pectin nasal citrate (FPNC) to
control these episodes.
Patients and methods. Seventeenpatientswith severe BP associated to routine radiotherapyprocedures andmaneuvers (simulation,
imagining acquisition, treatment delivery with external or brachytherapy), were selected to receive FPNC for pain relief. Most
patients (15/17) suffered from bone metastases and showed a low Karnovsky performance status (30–70%). BP intensity was
evaluated by Visual Analog Scale (VAS) before and after the procedures that triggered it. All patients described a very high VAS
value (9–10) related with the speciﬁc procedure. All patients were already receiving an opioid basal treatment at total dose
equivalent to 40–80mg morphine. BP was treated before the speciﬁc procedure with a dose of 100–400g of FPNC. Data related
to tolerance, pain relief, onset of the relief and efﬁcient dose to allow the procedure were collected.
Results. In all patients, BP score was reduced at least to 50% after 13min (5–30min) of fentanyl administration. Pain relief started
after 7min (5–15min) and the duration of the effect permitted the normal procedure development. All patients reported pain
control with a dose of 200g of FPNC except one patient who required progressive doses till 600g. Seven patients reported
minor undesirable effects related to the FPNC administration.
Conclusions. Procedures and maneuvers necessary to apply radiotherapy in ACP may provoke in some of them severe BP episodes,
so a strong and rapid analgesic is needed. FPNC offers a rapid absorption and pain relief, being particularly efﬁcient and well
accepted in these patients. This relief allows the completion of necessary procedures to administrate treatment without adding
unnecessary suffering to patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.585
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Introduction.Malnutrition andweight loss are common inpatientswith cancer (from8% to 87%) and can lead tonegative outcomes.
Cachexia and anorexia are their main causes, associated with stage and site – especially aerodigestive tumors. Radiotherapy
(RT) can produce an extra deterioration. Nevertheless, almost half of patients with RT receive nutritional assessment. Between
late 2012 – early 2013, we have developed a procedure whose objective is to implement a systematic method, by which make
individualized decisions, trying to solve nutrition problems and improve outcomes.
Purpose. To provide a description of the process and communicate data and reﬂections.
Methods and materials. The procedure, inspired in the Nutrition Care Process, consists of three steps: (a) nutritional assessment,
(b) intervention and (c) monitoring. We apply the Malnutrition Screening Tool (MST) and Patient-Generated Subjective Global
Assessment (PG-SGA) questionnaires to identify the risk and implement a plan. QLQ-c30 form to measure Quality of Life (QoL).
Nutrition intervention ranges from counseling (speciﬁc leaﬂets) to providing supplements, medications, tube feeding or referring
to other specialists. Monitoring includes follow-up and revising strategies. Nutritional status is re-assessed every 3 weeks after
starting RT (weekly in patients at higher risk), at the end and three months later.
Results and reﬂections. At 2 months, 25 patients have been included. Low risk patients maintained or improved overall QOL. Only
2 patients were classiﬁed as high risk. There are no interruptions because of malnutirition. This procedure has been planed to
be dynamically carried out, but we ﬁnd some difﬁculties: there can be more clinical problems, it takes long or collaboration with
other professionals may be difﬁcult.
Conclusions. Malnutrition is common in RT. Suitable screening tools and individualized intervention positively may inﬂuence
nutritional status, prognosis and QoL. Our workﬂow allows us to diagnose, treat and monitor patients with cancer and nutritional
needs.
http://dx.doi.org/10.1016/j.rpor.2013.03.586
